Bharat Parenterals growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr
Revenue+2.8%
EBITDA−24.1%
Net Income+14.2%
EPS (adj.)+14.2%
Total Assets+41.3%
Total Equity+15.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

BPLPHARMA₹1,912.90

Bharat Parenterals Limited

· Pharma & Health
₹ CrorePeersJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOCMcap ₹1,105 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
Revenue+2.8
EBITDA-24.1
Net Income+14.2
EPS (adj.)+14.2
Total Assets+41.3
Total Equity+15.0
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY23 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.